Can polycythemia vera (PV) cause a positive antinuclear antibody (ANA) test?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 19, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Can Polycythemia Vera Cause a Positive ANA?

No, polycythemia vera (PV) does not cause a positive antinuclear antibody (ANA) test—ANA positivity is not a recognized feature or diagnostic criterion of PV.

Why ANA is Not Associated with PV

The diagnostic criteria and clinical features of PV are well-established and do not include autoimmune markers like ANA:

  • PV diagnostic criteria focus on hematologic parameters and JAK2 mutations, not autoimmune markers. The WHO 2016 criteria require elevated hemoglobin/hematocrit, bone marrow hypercellularity with trilineage growth, and JAK2 V617F or exon 12 mutations 1, 2.

  • Characteristic clinical features of PV include erythrocytosis, aquagenic pruritus (48% of patients), splenomegaly, thrombocytosis, leukocytosis, and microvascular disturbances such as headaches and visual changes 2, 3. None of these involve autoimmune phenomena that would trigger ANA production.

  • Laboratory abnormalities in PV include low serum erythropoietin levels (>90% specificity), elevated leukocyte alkaline phosphatase, and increased vitamin B12 levels 1, 4—but autoimmune markers are conspicuously absent from all diagnostic algorithms and disease descriptions 1, 2, 4.

Clinical Implications

  • If a patient with PV has a positive ANA, consider this a coincidental finding or investigate for a separate autoimmune condition 2, 5. The prevalence of positive ANA in the general population (particularly low-titer positivity) means overlap can occur by chance.

  • Do not attribute autoimmune symptoms to PV itself—PV causes thrombotic complications (arterial thrombosis in 16%, venous thrombosis in 7%), bleeding risk with extreme thrombocytosis, and progression to myelofibrosis (12.7%) or acute myeloid leukemia (6.8%) 3, 5, but not autoimmune manifestations.

  • The diagnostic workup for PV should focus on JAK2 mutation testing (positive in >95% of cases), serum erythropoietin measurement, and bone marrow examination when indicated 2, 4, 5—not on autoimmune serologies.

Common Pitfall to Avoid

  • Do not confuse PV with secondary causes of erythrocytosis or other hematologic conditions that might coexist with autoimmune disease 1, 4. If ANA is positive, pursue a separate diagnostic evaluation for connective tissue disease rather than assuming it relates to the myeloproliferative neoplasm.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Diagnosis and Management of Polycythemia Rubra Vera

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Guideline

Diagnostic Approach for Polycythemia Vera

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.